Risk Stratification of Sudden Cardiac Death in Patients with Heart Failure: An update

Daniele Masarone1, Giuseppe Limongelli2,3,4, Ernesto Ammendola5

  • 1Heart Failure Unit, AORN dei Colli, Monaldi Hospital, 80121 Naples, Italy. danielemasarone@libero.it.

Insights

Sudden cardiac death (SCD) risk stratification in heart failure (HF) patients with preserved (HFpEF) or reduced ejection fraction (HFrEF) remains challenging. This review updates current strategies for identifying high-risk individuals to prevent SCD.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Cardiovascular Research

Background:

  • Heart failure (HF) is a complex syndrome with high mortality, often due to sudden cardiac death (SCD) or progressive pump failure.
  • Over 80% of HF deaths are cardiovascular, highlighting the need for effective risk stratification.
  • Differentiating risk in HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF) is crucial.

Purpose of the Study:

  • To provide an updated overview of current strategies for SCD risk stratification.
  • To address the specific challenges in risk stratifying both HFpEF and HFrEF patients.
  • To consolidate current knowledge for clinicians and researchers.

Main Methods:

  • Literature review of recent studies and clinical guidelines.
  • Analysis of risk factors and predictive models for SCD in HF.
  • Comparative assessment of stratification methods for HFpEF and HFrEF.

Main Results:

  • Current risk stratification for SCD in HF is complex and evolving.
  • Specific challenges exist in identifying SCD risk in HFpEF compared to HFrEF.
  • Emerging biomarkers and imaging techniques show promise.

Conclusions:

  • Effective SCD risk stratification is essential for improving outcomes in heart failure patients.
  • Tailored strategies are needed for HFpEF and HFrEF populations.
  • Continued research is vital to refine SCD prediction and prevention in HF.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319